Inovio Pharmaceuticals, Inc. (INO) Posts Q2 Loss of 2c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.16 +2.65%
EPS Growth %: +75.9%
Financial Fact:
Net loss: -20.76M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: +75.9%
Financial Fact:
Net loss: -20.76M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q2 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $1.79 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- Worthington Steel, Inc. (WS) Misses Q1 EPS by 11c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
